Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Aktis raises funds, strikes deals for actinium-based cancer therapies

by Michael McCoy
August 28, 2022 | A version of this story appeared in Volume 100, Issue 30

 

Aktis Oncology has raised $84 million to advance the use of alpha emitters as radiopharmaceuticals for cancer. The fundraising is an extension of Aktis’s March 2021 series A financing of $72 million. The big drug firms Novartis and Bristol Myers Squibb participated both times, and Merck & Co. is a new investor. Separately, Aktis says it has signed supply agreements for actinium-225, an alpha emitter, with three medical radioisotope producers: NorthStar Medical Radioisotopes, Niowave, and TerraPower.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.